We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more here.Close Me
On December 19, 2018, the Central Drugs Standard Control
Organization (CDSCO) re-issued safety guidelines15 for
'Isotretinoin' following public grievances related to
drug's Adverse Drugs Reaction received at Centralized Public
Grievance Redress and Monitoring System (CPGRAMS). Isotretinoin, is
an oral drug used for the treatment and prevention of severe acne.
The safety guidelines are published after consultation with Subject
Expert Committee16 (SEC), CDSCO, where the committee
examined the risk/benefit profile of drug for the approved
indications in the country, and recommended that the drug may cause
severe birth defects during the course of treatment. Therefore, the
CDSCO directed all the State and Union Territories' drugs
controllers to inform manufacturer/distributer/retail chemists
under their jurisdiction to comply with the following safety
guidelines:
The drug should be sold only on the
prescription of a dermatologist.
The patients should sign a consent
form before undertaking the treatment.
The Pack of the drug should carry box
warning saying "the drug may cause severe birth defect;
you must not take this medicine if you are pregnant or may likely
to become pregnant during treatment". It also mentions
that "You should also avoid pregnancy for 6 months after
stopping the treatment".
The manufacturers should provide a
package insert along with their product in major local
languages.
The retail chemists should maintain
the details of retail sale of the drug.
About Isotretinoin
Isotretinoin is a Retinoid, a naturally-occurring retinoic acid
act and binds to the nuclear retinoic acid receptors (RARs),
activated RARs serve as transcription factors that promote cell
differentiation and apoptosis. This agent also exhibits
immunomodulatory and anti-inflammatory responses and inhibits
ornithine decarboxylase, thereby decreasing polyamine synthesis and
keratinization. It is used as a topical dermatologic agent that is
used in the treatment of ACNE VULGARIS and several other skin
diseases17.
Note - Isotretinoin capsules 10mg and 20 mg
were approved by the CDSCO in June 2002 for cystic and conglobate
acne, severe nodular acne unresponsive to antibiotic therapy with
various conditions. The said approval also comprised with boxed
warning for female patients that 'the drug may cause severe
birth defect and patient should sign a consent form before
undertaking treatment'. At present the drug is available in
Indian market with various brand names like Acneone, Acnex-20,
Across, Aktret, Ratino and Isopad.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Digital innovation, driven by Artificial Intelligence (AI) will undoubtedly bring the next wave of significant disruption to the healthcare industry, impacting organizations in myriad ways.
Amidst the on-going heated debate on expanding the scope of the pharmaceuticals and medical devices being subject to price control, the Department of Pharmaceuticals recently notified certain exemptions ...
"It is easy to get a thousand prescriptions, but hard to get one single remedy" so goes a popular Chinese proverb which succinctly summaries the pharmacy market in India and the debate surrounding e-pharmacies.